PHIO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Phio Therapeutics reached a key development milestone for PH-762 with an FDA submission supporting the next stage of clinical development in cutaneous squamous cell carcinomaSep 14, 2026
- Phio Pharmaceuticals received a U.S. Notice of Allowance for its INTASYL composition targeting the BRD4 protein with PH-894Aug 11, 2026
- Phio reported a positive safety monitoring committee conclusion for lead candidate PH-762 in a skin cancer trialFeb 10, 2026
- Phio Pharmaceuticals announced completion of enrollment in Phase 1b clinical trial of INTASYL siRNA lead compound PH-762Nov 26, 2025
- Phio Pharmaceuticals announces INTASYL PH-762 is named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award programNov 7, 2025